Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal

G. Pizzocaro, F. Zanoni, A. Milani, R. Salvioni, L. Piva, S. Pilotti, E. Bombardieri, J. D. Tesoro-Tess, R. Musumeci

Research output: Contribution to journalArticle

Abstract

Sixty-two consecutive patients with clinical stage I nonseminomatous testicular cancer were entered into a prospective study to receive no treatment after orchiectomy until clinical evidence of recurrent disease. Of 59 evaluable cases, 41 (69.5%) remained continuously disease free for a median duration of 30 months (range, 18 to 46 months), and evidence of metastatic disease developed in 18 patients (30.5%) from 2 to 36 months after orchiectomy. The median disease-free interval for relapsing patients was 6 months. Retroperitoneal metastases developed in ten patients; seven patients had pulmonary metastases, and one patient had progressive elevation of the serum α-fetoprotein level. Relapses were significantly more frequent in patients with either embryonal carcinoma, infiltrating testicular cancer (pT > 1), peritumoral vascular invasion, or in those who underwent transscrotal biopsy. One patient with relapse refused salvage therapy and died. The remaining 17 patients have been rendered disease free with cisplatin combination chemotherapy and/or surgery. However, two patients showed further recurrence, with one in the lung and the other one also in the retroperitoneal nodes. In our opinion, surveillance following orchiectomy will provide useful information in clinical stage I nonseminomatous testicular cancer, but it is a difficult study. For the time being, it should be restricted to specialized centers only. In the meanwhile, retroperitoneal lymphadenectomy remains the standard treatment.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalJournal of Clinical Oncology
Volume4
Issue number1
Publication statusPublished - 1986

Fingerprint

Orchiectomy
Testicular Neoplasms
Recurrence
Fetal Proteins
Embryonal Carcinoma
Neoplasm Metastasis
Salvage Therapy
Lung
Combination Drug Therapy
Lymph Node Excision
Cisplatin
Blood Vessels
Prospective Studies
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pizzocaro, G., Zanoni, F., Milani, A., Salvioni, R., Piva, L., Pilotti, S., ... Musumeci, R. (1986). Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal. Journal of Clinical Oncology, 4(1), 35-40.

Orchiectomy alone in clinical stage I nonseminomatous testis cancer : A critical appraisal. / Pizzocaro, G.; Zanoni, F.; Milani, A.; Salvioni, R.; Piva, L.; Pilotti, S.; Bombardieri, E.; Tesoro-Tess, J. D.; Musumeci, R.

In: Journal of Clinical Oncology, Vol. 4, No. 1, 1986, p. 35-40.

Research output: Contribution to journalArticle

Pizzocaro, G, Zanoni, F, Milani, A, Salvioni, R, Piva, L, Pilotti, S, Bombardieri, E, Tesoro-Tess, JD & Musumeci, R 1986, 'Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal', Journal of Clinical Oncology, vol. 4, no. 1, pp. 35-40.
Pizzocaro, G. ; Zanoni, F. ; Milani, A. ; Salvioni, R. ; Piva, L. ; Pilotti, S. ; Bombardieri, E. ; Tesoro-Tess, J. D. ; Musumeci, R. / Orchiectomy alone in clinical stage I nonseminomatous testis cancer : A critical appraisal. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 1. pp. 35-40.
@article{edd9545a111f428c9e457f5b61218f98,
title = "Orchiectomy alone in clinical stage I nonseminomatous testis cancer: A critical appraisal",
abstract = "Sixty-two consecutive patients with clinical stage I nonseminomatous testicular cancer were entered into a prospective study to receive no treatment after orchiectomy until clinical evidence of recurrent disease. Of 59 evaluable cases, 41 (69.5{\%}) remained continuously disease free for a median duration of 30 months (range, 18 to 46 months), and evidence of metastatic disease developed in 18 patients (30.5{\%}) from 2 to 36 months after orchiectomy. The median disease-free interval for relapsing patients was 6 months. Retroperitoneal metastases developed in ten patients; seven patients had pulmonary metastases, and one patient had progressive elevation of the serum α-fetoprotein level. Relapses were significantly more frequent in patients with either embryonal carcinoma, infiltrating testicular cancer (pT > 1), peritumoral vascular invasion, or in those who underwent transscrotal biopsy. One patient with relapse refused salvage therapy and died. The remaining 17 patients have been rendered disease free with cisplatin combination chemotherapy and/or surgery. However, two patients showed further recurrence, with one in the lung and the other one also in the retroperitoneal nodes. In our opinion, surveillance following orchiectomy will provide useful information in clinical stage I nonseminomatous testicular cancer, but it is a difficult study. For the time being, it should be restricted to specialized centers only. In the meanwhile, retroperitoneal lymphadenectomy remains the standard treatment.",
author = "G. Pizzocaro and F. Zanoni and A. Milani and R. Salvioni and L. Piva and S. Pilotti and E. Bombardieri and Tesoro-Tess, {J. D.} and R. Musumeci",
year = "1986",
language = "English",
volume = "4",
pages = "35--40",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Orchiectomy alone in clinical stage I nonseminomatous testis cancer

T2 - A critical appraisal

AU - Pizzocaro, G.

AU - Zanoni, F.

AU - Milani, A.

AU - Salvioni, R.

AU - Piva, L.

AU - Pilotti, S.

AU - Bombardieri, E.

AU - Tesoro-Tess, J. D.

AU - Musumeci, R.

PY - 1986

Y1 - 1986

N2 - Sixty-two consecutive patients with clinical stage I nonseminomatous testicular cancer were entered into a prospective study to receive no treatment after orchiectomy until clinical evidence of recurrent disease. Of 59 evaluable cases, 41 (69.5%) remained continuously disease free for a median duration of 30 months (range, 18 to 46 months), and evidence of metastatic disease developed in 18 patients (30.5%) from 2 to 36 months after orchiectomy. The median disease-free interval for relapsing patients was 6 months. Retroperitoneal metastases developed in ten patients; seven patients had pulmonary metastases, and one patient had progressive elevation of the serum α-fetoprotein level. Relapses were significantly more frequent in patients with either embryonal carcinoma, infiltrating testicular cancer (pT > 1), peritumoral vascular invasion, or in those who underwent transscrotal biopsy. One patient with relapse refused salvage therapy and died. The remaining 17 patients have been rendered disease free with cisplatin combination chemotherapy and/or surgery. However, two patients showed further recurrence, with one in the lung and the other one also in the retroperitoneal nodes. In our opinion, surveillance following orchiectomy will provide useful information in clinical stage I nonseminomatous testicular cancer, but it is a difficult study. For the time being, it should be restricted to specialized centers only. In the meanwhile, retroperitoneal lymphadenectomy remains the standard treatment.

AB - Sixty-two consecutive patients with clinical stage I nonseminomatous testicular cancer were entered into a prospective study to receive no treatment after orchiectomy until clinical evidence of recurrent disease. Of 59 evaluable cases, 41 (69.5%) remained continuously disease free for a median duration of 30 months (range, 18 to 46 months), and evidence of metastatic disease developed in 18 patients (30.5%) from 2 to 36 months after orchiectomy. The median disease-free interval for relapsing patients was 6 months. Retroperitoneal metastases developed in ten patients; seven patients had pulmonary metastases, and one patient had progressive elevation of the serum α-fetoprotein level. Relapses were significantly more frequent in patients with either embryonal carcinoma, infiltrating testicular cancer (pT > 1), peritumoral vascular invasion, or in those who underwent transscrotal biopsy. One patient with relapse refused salvage therapy and died. The remaining 17 patients have been rendered disease free with cisplatin combination chemotherapy and/or surgery. However, two patients showed further recurrence, with one in the lung and the other one also in the retroperitoneal nodes. In our opinion, surveillance following orchiectomy will provide useful information in clinical stage I nonseminomatous testicular cancer, but it is a difficult study. For the time being, it should be restricted to specialized centers only. In the meanwhile, retroperitoneal lymphadenectomy remains the standard treatment.

UR - http://www.scopus.com/inward/record.url?scp=0022644270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022644270&partnerID=8YFLogxK

M3 - Article

C2 - 3941332

AN - SCOPUS:0022644270

VL - 4

SP - 35

EP - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -